Latest news with #NTUH
Fox News
29-04-2025
- Health
- Fox News
World's first continuous beating heart transplant
For the first time ever, surgeons at National Taiwan University Hospital (NTUH) successfully performed a heart transplant in which the donor organ never stopped beating. This revolutionary procedure eliminates the traditional pause in blood flow, known as ischemic time, dramatically reducing damage to the heart muscle and improving the chances of a successful transplant. By keeping the heart continuously pumping oxygenated blood throughout the entire process, NTUH has set a new benchmark in cardiac surgery that promises better outcomes for patients worldwide. Join The FREE "CyberGuy Report": Get my expert tech tips, critical security alerts and exclusive deals, plus instant access to my free "Ultimate Scam Survival Guide" when you sign up. Traditional heart transplants rely on cold storage, which pauses blood flow to the organ. Even a few hours without oxygen can damage heart muscle, raising the risks of rejection or complications post-surgery. NTUH's method? A custom organ care system that acts like a portable life-support machine, delivering oxygenated blood to the heart from donor to recipient; no pauses, no cold storage. Inspired by ECMO life support, NTUH's organ care system keeps the heart pumping outside the body using a system of pumps, oxygenators and reservoirs. During the first surgery, the team transported a donor heart between operating rooms while it was still beating, hooked up to this device. The recipient, a 49-year-old woman with dilated cardiomyopathy, recovered smoothly and showed remarkably low cardiac enzyme levels, which is a key indicator of heart muscle health. While Stanford University pioneered "beating-heart" transplants in 2023, their method still included brief ischemic periods (10–30 minutes) during organ transfer. NTUH's zero-ischemic approach? The heart never stopped, not even for a second. "The hearts were still beating before procurement, continued beating after procurement and never stopped," said Chen Yih-shurng, head of NTUH's organ transplant team. With two successful transplants under their belt, NTUH aims to refine the organ care system and expand access. Their groundbreaking findings, published in the Journal of Thoracic and Cardiovascular Surgery Techniques, could redefine global transplant protocols. As demand for donor hearts outpaces supply, this innovation offers hope for shorter wait lists and healthier recoveries. NTUH's milestone isn't just about technical prowess, it's about saving lives. By cutting out ischemic time, they've turned "impossible" into "I'm possible." For patients awaiting transplants, this breakthrough means stronger donor hearts, fewer complications and a brighter shot at a second chance. As the team puts it, zero ischemic time equals zero unnecessary risks. After learning about this new procedure, do you feel more hopeful about organ transplants? Why or why not? Let us know by writing us at For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Follow Kurt on his social channels: Answers to the most-asked CyberGuy questions: New from Kurt: Copyright 2025 All rights reserved.
Los Angeles Times
19-04-2025
- Health
- Los Angeles Times
Advancing World-Class Healthcare Through Technology and Global Partnerships
Taiwan's hospital system is rapidly emerging as a global leader in medical innovation, integrating advanced technologies and pioneering care models. With a strong emphasis on digital transformation and international collaboration – particularly with the United States – Taiwan's leading institutions are setting new benchmarks in patient care, research, and cross-border partnerships. A defining strength of Taiwan's healthcare system is its embrace of digital innovation. Hospitals across the country are leveraging AI-assisted diagnostics, smart imaging, and integrated electronic medical records. Taipei Veterans General Hospital (TVGH), for example, is implementing nearly 80 AI-driven projects. 'We focus on smart healthcare, precision medicine and frontier medicine, with our primary objectives being to enhance patient safety and healthcare quality,' said Dr. Wei-Ming Chen, Superintendent of TVGH. National Taiwan University Hospital (NTUH) is also leading in this space. 'Our team developed the world's first AI-powered CT system for early pancreatic cancer diagnosis,' said Dr. Ming-Shiang Wu, NTUH Superintendent. 'We're combining innovation with patient-centered care to improve outcomes across Taiwan and beyond.' Telemedicine and mobile platforms are expanding access to care in both urban and rural areas. Real-time dashboards, robotic assistance, and smart ICUs are also becoming standard in major hospitals, reducing staff burden while increasing service efficiency. From advanced gene therapies to regenerative medicine, Taiwan is pushing the frontiers of personalized care. Hospitals are developing cell therapies, genome analysis systems, and AI tools to guide treatment. TVGH's 'Magic Bison' platform, for instance, enables real-time whole genome analysis to support clinicians with instant diagnostics and drug recommendations. Private-sector innovators are also driving biomedical advances. 'We specialize in tissue regeneration, and our strength lies in developing structural scaffolds for cell therapy and repair,' said Ms. Changhui Chen, CEO of Han Biomedical. 'With licenses from the TFDA and upcoming approvals in Europe, we're positioning Taiwan as a serious player in global regenerative medicine.' Taiwan's medical ecosystem is increasingly attractive for international partnerships. NTUH is engaged in multicenter trials with global pharmaceutical companies. 'Taiwan's strengths in semiconductors, ICT, and healthcare data give us a competitive edge in AI and advanced medicine,' Dr. Wu said. Maria Von Biotechnology is taking a translational approach to international growth. 'Our goal is to bridge research and real-world application – what we call 'bench to bed,'' explained Dr. William Hung, CEO. 'We're launching clinics and talent partnerships to close the gap between R&D and practical treatment.' Chairwoman Dr. Mei-Yue Huang added, 'Taiwan's recent regulatory reforms in regenerative medicine and exosomes give us a clear path to commercialization, especially in personalized care.' As healthcare systems worldwide grapple with rising demands, Taiwan offers a scalable model rooted in innovation, digital infrastructure, and public-private cooperation. Hospitals are investing in green healthcare, talent development, and interdisciplinary collaboration to stay ahead of emerging global challenges. 'We believe the commercial future of Taiwan's biotech sector depends on connecting our creativity with stronger talent pipelines and better global marketing,' said Ms. Chen. 'The innovation is already here – we just need to bring it to the world.' By fusing advanced science with a culture of patient-centered care, Taiwan's healthcare leaders are not just adapting to the future – they are helping define it.
Yahoo
17-04-2025
- Business
- Yahoo
Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration
In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied. HSINCHU, April 17, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, announced the preliminary results of a research collaboration with the National Taiwan University Hospital (NTUH) on breast cancer patients. The study found that JelloX's 3D pathology technology identified a significantly increased proportion of tumors with HER2-low and HER2-ultralow expression compared to conventional methods, demonstrating this technology's increased sensitivity and potential as a superior diagnostic tool for HER2 detection in breast cancers. Contact JelloX at sales@ to explore partnerships and learn more about the company's cutting-edge 3D pathology technology. According to the US National Cancer Institute, breast cancer is the most prevalent form of cancer. However, the difficulty of precisely determining treatment has made the identification of HER2 expression essential. In HER2-low and HER2-ultralow metastatic breast cancer, the novel antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has demonstrated robust efficacy over conventional chemotherapy. Yet considering HER2 spatial heterogeneity, traditional diagnostic methods have shown to be less precise than 3D pathology in detecting the presence of the HER2 protein. "For the specific challenges posed by metastatic breast cancer and the need to identify predictive biomarkers accurately, the high sampling capacity of 3D pathology holds particular potential," commented Dr. Yen-Yin Lin, CEO of JelloX. "JelloX Biotech's Comprehensive HER2 Diagnostic Solution is poised to revolutionize HER2 diagnostics. With a more comprehensive data set on tumor samples, healthcare providers can be empowered to make more precise diagnoses, ensuring that the right patients receive the right treatment at the right time." New findings with NTUH on HER2 breast cancer In JelloX's research collaboration with NTUH, preliminary findings indicate that more than half of the analyzed cases exhibited diagnostic discrepancies when re-evaluated using the company's advanced 3D pathology methods. Notably, among patients initially classified as HER2-null by traditional methods, more than 66.7% were reclassified as HER2-expressing (HER2-low or HER2-ultralow) using 3D technology, thereby becoming potentially eligible for T-DXd treatment. These findings echo the company's recent results using samples from colorectal and esophageal cancers, demonstrating that 3D pathology may have broader potential across various cancer types. The full findings will be shared at the Global Breast Cancer Conference in South Korea on April 17. Implications for breast cancer treatment and drug guidelines T-DXd has demonstrated significant efficacy in tumors with HER2 expression. However, tumors classified as HER2-null under conventional pathological testing are ineligible for T-DXd treatment. By detecting HER2 more precisely using 3D pathology methods, we can identify more patients eligible for T-DXd therapy. In addition to cancer patients, JelloX's 3D pathology technology has the potential to expand possibilities across healthcare stakeholders: For physicians: This advanced diagnostic tool offers a more comprehensive patient data set and, when integrated with AI, helps reduce physician workloads. For pharmaceutical companies and research institutions: The technology enhances companion diagnostics (CDx) for drug usage and is a valuable tool for new drug development. For healthcare systems: 3D pathology optimizes medical resource allocation and minimizes unnecessary financial and healthcare burdens. About JelloX Biotech Inc. Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup that focuses on advancing cancer pathology through 3D digital imaging and AI technology. For more information, please visit: View original content to download multimedia: SOURCE JelloX Biotech Inc. Sign in to access your portfolio
Yahoo
16-03-2025
- Health
- Yahoo
At NVIDIA GTC 2025, DeCloak Intelligences and NTUH's Hsin-Chu Branch will exhibit their AI privacy healthcare system
A featured presentation will be "Enhance Patient Safety With Privacy-Preserving AI: Multimodal DNN and VLM for Event Detection in Healthcare." SAN JOSE, Calif. and TAIPEI, March 16, 2025 /PRNewswire/ -- DeCloak Intelligences, a subsidiary of Etron Technology (TPEx: 5351), is set to showcase its groundbreaking 'AI-aided Privacy Agent (AipA) Healthcare System' at NVIDIA's GTC 2025 with the Hsin-Chu Branch of National Taiwan University Hospital (NTUH), scheduled from March 17–21, 2025, in San Jose, California. This innovative system leverages patented AI de-identification technology to enhance medical efficiency while ensuring patient privacy and safety. The 'AipA Healthcare System' performs real-time de-identification image processing, significantly reducing the risk of personal data leakage. It offers a suite of AI recognition functions, including patient identity verification, tracking within medical facilities, and detection of critical events such as falls or violent incidents. These capabilities aim to bolster the safety and efficiency of healthcare environments. Currently, this system has been implemented in the public areas and demonstration wards of the NTUH Hsin-Chu Branch Zhubei Campus. Using AI automatic recognition technology, it ensures the image privacy of patients and medical staff without affecting medical operations. Additionally, it reduces the risk of medical violence, further enhancing the safety within the hospital. At GTC 2025, Dr. Yao-Tung Tsou, President of DeCloak Intelligences, will present a session titled "Enhance Patient Safety With Privacy-Preserving AI: Multimodal DNN and VLM for Event Detection in Healthcare." This presentation will delve into the integration of privacy-enhancing technologies with multimodal deep neural networks (DNN) and vision-language models (VLM). This system integrates differentially private AI models with identity recognition and event detection to perform critical tasks such as fall detection, identifying dangerous activities, and recognizing elderly patients without exposing image data. This advancement builds upon DeCloak's award-winning privacy solutions, including the DeCloakVision surveillance system and DeCloakFace facial recognition technology, which have been deployed in smart healthcare and automotive environments. The integration of VLM represents a significant leap forward in balancing data utility with privacy preservation, addressing ethical concerns associated with AI in healthcare, all while adhering to stringent compliance standards, including GDPR, CCPA, and Taiwan's Personal Information Protection Act. DeCloak stated that the company had a brilliant showing at the 2025 Consumer Electronics Show (CES) in the United States, successfully demonstrating a number of innovative technologies and solutions, including the CES Innovation Award-winning DeCloakVision surveillance system and DeCloakFace facial recognition technology, significantly enhancing the brand's international recognition. During the exhibition, DeCloak engaged in in-depth exchanges with industry representatives and investors from Europe, the Americas, and Asia, attracting the attention of many potential customers, which not only deepened relationships with existing partners but also successfully expanded new cooperation opportunities. Looking ahead, DeCloak will continue to expand its international presence and will soon travel to the United States to participate in NVIDIA GTC – an important AI semiconductor exhibition. NVIDIA GTC is a premier event in the global AI and high-performance computing fields, attracting technical experts, academic institutions, and industry leaders worldwide. DeCloak Intelligences' participation underscores Taiwan's active engagement in smart healthcare innovation. The company aims to expand Taiwan's smart healthcare technology. National Taiwan University Hospital, Hsinchu Branch, utilizes DeCloak's " AI-aided Privacy Agent (AipA) Healthcare System " for de-identified image processing, reducing the risk of personal image data leakage. About DeCloakDeCloak's privacy computing solutions can be deployed through either software or hardware. With DeCloak's patented corresponding AI prediction algorithm, all data processed can remain highly analyzable while preserving total privacy. The processed data is transmitted to the local server or cloud in a de-identified format, and enterprises can use the AI prediction model to run data analysis and architect big data About Etron Technology, Technology, Inc. (TPEx: 5351. TW) is a world-class fabless and heterogeneous integration IC design company that specializes in the application-driven buffer memory, known-good die memory (KGDM), and long-retention time DRAM (RPC DRAM), and other artificial intelligence and machine learning-induced DRAM products. Etron also develops system-in-packages, including high-speed transfer interface chips of USB Type-C and 3D depth sensing computer vision and panoramic image capturing chips. Media Contact:Etron Tech - Ms. Justine Tsai, Tel: +886-3-578-2345 #8670, Email: pr@ - Ms. Vicki Chang, Tel:+886-2-8751-1691 #2204, Email: vchang@ View original content to download multimedia: SOURCE Etron Technology; DeCloak Intelligences Sign in to access your portfolio
Associated Press
16-03-2025
- Health
- Associated Press
At NVIDIA GTC 2025, DeCloak Intelligences and NTUH's Hsin-Chu Branch will exhibit their AI privacy healthcare system
A featured presentation will be 'Enhance Patient Safety With Privacy-Preserving AI: Multimodal DNN and VLM for Event Detection in Healthcare.' SAN JOSE, Calif. and TAIPEI, March 16, 2025 /PRNewswire/ -- DeCloak Intelligences, a subsidiary of Etron Technology (TPEx: 5351), is set to showcase its groundbreaking 'AI-aided Privacy Agent (AipA) Healthcare System' at NVIDIA's GTC 2025 with the Hsin-Chu Branch of National Taiwan University Hospital (NTUH), scheduled from March 17–21, 2025, in San Jose, California. This innovative system leverages patented AI de-identification technology to enhance medical efficiency while ensuring patient privacy and safety. The 'AipA Healthcare System' performs real-time de-identification image processing, significantly reducing the risk of personal data leakage. It offers a suite of AI recognition functions, including patient identity verification, tracking within medical facilities, and detection of critical events such as falls or violent incidents. These capabilities aim to bolster the safety and efficiency of healthcare environments. Currently, this system has been implemented in the public areas and demonstration wards of the NTUH Hsin-Chu Branch Zhubei Campus. Using AI automatic recognition technology, it ensures the image privacy of patients and medical staff without affecting medical operations. Additionally, it reduces the risk of medical violence, further enhancing the safety within the hospital. At GTC 2025, Dr. Yao-Tung Tsou, President of DeCloak Intelligences, will present a session titled 'Enhance Patient Safety With Privacy-Preserving AI: Multimodal DNN and VLM for Event Detection in Healthcare.' This presentation will delve into the integration of privacy-enhancing technologies with multimodal deep neural networks (DNN) and vision-language models (VLM). This system integrates differentially private AI models with identity recognition and event detection to perform critical tasks such as fall detection, identifying dangerous activities, and recognizing elderly patients without exposing image data. This advancement builds upon DeCloak's award-winning privacy solutions, including the DeCloakVision surveillance system and DeCloakFace facial recognition technology, which have been deployed in smart healthcare and automotive environments. The integration of VLM represents a significant leap forward in balancing data utility with privacy preservation, addressing ethical concerns associated with AI in healthcare, all while adhering to stringent compliance standards, including GDPR, CCPA, and Taiwan's Personal Information Protection Act. DeCloak stated that the company had a brilliant showing at the 2025 Consumer Electronics Show (CES) in the United States, successfully demonstrating a number of innovative technologies and solutions, including the CES Innovation Award-winning DeCloakVision surveillance system and DeCloakFace facial recognition technology, significantly enhancing the brand's international recognition. During the exhibition, DeCloak engaged in in-depth exchanges with industry representatives and investors from Europe, the Americas, and Asia, attracting the attention of many potential customers, which not only deepened relationships with existing partners but also successfully expanded new cooperation opportunities. Looking ahead, DeCloak will continue to expand its international presence and will soon travel to the United States to participate in NVIDIA GTC – an important AI semiconductor exhibition. NVIDIA GTC is a premier event in the global AI and high-performance computing fields, attracting technical experts, academic institutions, and industry leaders worldwide. DeCloak Intelligences' participation underscores Taiwan's active engagement in smart healthcare innovation. The company aims to expand Taiwan's smart healthcare technology. National Taiwan University Hospital, Hsinchu Branch, utilizes DeCloak's " AI-aided Privacy Agent (AipA) Healthcare System " for de-identified image processing, reducing the risk of personal image data leakage. About DeCloak DeCloak's privacy computing solutions can be deployed through either software or hardware. With DeCloak's patented corresponding AI prediction algorithm, all data processed can remain highly analyzable while preserving total privacy. The processed data is transmitted to the local server or cloud in a de-identified format, and enterprises can use the AI prediction model to run data analysis and architect big data trends. About Etron Technology, Inc. Etron Technology, Inc. (TPEx: 5351. TW) is a world-class fabless and heterogeneous integration IC design company that specializes in the application-driven buffer memory, known-good die memory (KGDM), and long-retention time DRAM (RPC DRAM), and other artificial intelligence and machine learning-induced DRAM products. Etron also develops system-in-packages, including high-speed transfer interface chips of USB Type-C and 3D depth sensing computer vision and panoramic image capturing chips.
